Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
about
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersPalmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasisPatient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis.Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical settingPatient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practiceValidity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasisPatient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasisTreatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England.Diagnosis and treatment of pediatric psoriasis: current and future.OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.Serious infections among a large cohort of subjects with systemically treated psoriasis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Implications of treatment resistant severe psoriasis for benchmarking quality of care.Eliciting preferences to inform patient-centred policies: the case of psoriasis.Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.Intentional and unintentional medication non-adherence in psoriasis: the role of patients' medication beliefs and habit strength.PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis.
P2860
Q26771785-044C55B0-1F54-4ED9-9962-0346A8454181Q34194956-8281669A-7166-4848-83A5-472BD3C18F05Q34196035-6BB51901-190E-488E-AEED-A1FDD963A14EQ34563661-9C3A7C4F-A825-4C02-B27B-EC6E625C0AEFQ34743112-F89A5B86-F9CA-4AF6-AFF6-B2C20A70264BQ34997467-3EF34E47-3151-47B3-8CBB-3A41F3A2FFBBQ36172752-C1551C9C-C046-42B2-B7CD-8F746C88AF9DQ36368478-C73BD038-D6B2-49E4-BAEE-D81FC763A6B2Q36816617-F71E101E-0656-49E4-BD85-5F0B5DD0AB1BQ38075573-17B8071A-BADF-49FA-9C8C-3ED41E208A60Q38107168-D7B6FCB1-24B1-4D47-9D7B-5B9207B43C7FQ38545195-1FABA51E-1D14-40B3-8DDA-C2CBE4A55476Q38993275-F88B93AB-74DB-4180-84FA-3B6C24C1BC2FQ40209526-023DBEE5-220A-48A2-8BAC-4FA92AF44F0FQ40261663-B26D858F-8BB0-4C82-8296-BA2B633409D3Q42448043-24C94B38-0E3A-4E97-95E5-91365721F281Q46731189-C16071E2-03D3-40E7-8C7D-C1A2567CA6D4Q47644680-284B19FF-D6EE-49B5-869F-C95556F8DED7Q47675710-6E80FE1C-51F0-4281-B07F-ACAF9111D995Q48093596-8A2D4C38-F44F-422F-BF51-647FB1F9A824Q48298598-C0B5CA61-DF7C-43E0-A129-5CC227AA1C2EQ49568162-4AF0E4BF-423A-4304-9D47-55183E22EADFQ50068335-3E0B65CC-2FAC-458D-A94D-9C346CE97476Q50333986-69E58643-4DBD-4158-A4D6-05985EB0B932
P2860
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Comparative effectiveness of c ...... the clinical practice setting.
@ast
Comparative effectiveness of c ...... the clinical practice setting.
@en
type
label
Comparative effectiveness of c ...... the clinical practice setting.
@ast
Comparative effectiveness of c ...... the clinical practice setting.
@en
prefLabel
Comparative effectiveness of c ...... the clinical practice setting.
@ast
Comparative effectiveness of c ...... the clinical practice setting.
@en
P2093
P2860
P50
P1433
P1476
Comparative effectiveness of c ...... the clinical practice setting
@en
P2093
Abby S Van Voorhees
Brian R Sperber
Bruce A Brod
Bruce F Bebo
Daniel B Shin
Gerald G Krueger
Jamie D Weisman
Jane M Steinemann
Jennifer Goldfarb
P2860
P304
P356
10.1001/ARCHDERMATOL.2012.370
P577
2012-04-01T00:00:00Z